MedTrace Logo

Trial to Evaluate Bioequivalence of LCB01-0371 in Different Batches

NCT04939779 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 25

Last updated 2021-06-25

No results posted yet for this study

Summary

The objective of this clinical trial is to evaluate bioequivalence of "LCB01-0371 (Batch# 1650006)" and "LCB01-0371(Batch#3183817R) in healthy adult subject

Conditions

  • Healthy

Interventions

DRUG

LCB01-0371 tablet 400mg (Test drug, Batch# 3183817R)

Oral administration

DRUG

LCB01-0371 tablet 400mg (Reference drug, Batch# 1650006)

Oral administration

Sponsors & Collaborators

  • LigaChem Biosciences, Inc.

    lead INDUSTRY

Principal Investigators

  • Jae-Yong Chung · Seoul National University Bundang Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
19 Years
Max Age
45 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2021-01-14
Primary Completion
2021-01-24
Completion
2021-02-01

Countries

  • South Korea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04939779 on ClinicalTrials.gov